Glutamatergic and GABAergic reactivity and cognition in 22q11.2 deletion syndrome and healthy volunteers: A randomized double-blind 7-Tesla pharmacological MRS study

Claudia Vingerhoets1,2, Desmond HY Tse3, Mathilde van Oudenaren1,2, Dennis Hernaus1, Esther van Duin1, Janneke Zinkstok4, Johannes G Ramaekers3, Jacobus FA Jansen5, Grainne McAlonan6 and Therese van Amelsvoort1

Abstract
Aims: 22q11.2 deletion syndrome (22q11.2DS) is associated with impaired cognitive functioning. Glutamatergic pathways have been linked with cognition and are hypothesized to be disrupted in 22q11.2DS patients, possibly ‘shifting’ the excitatory (glutamate)/inhibitory (GABA) balance. Hence, the glutamate/GABA balance may constitute a target for pharmacological treatment. We aimed to examine alterations of glutamate/GABA metabolites in 22q11.2DS in vivo using riluzole, a compound with glutamate/GABA-modulating action, as pharmacological challenge.

Methods: Seventeen 22q11.2DS patients and 20 matched healthy controls were enrolled in this randomized double-blind placebo-controlled crossover study. Glutamate and glutamine concentrations in the anterior cingulate cortex (ACC) and striatum, as well as ACC GABA concentrations were obtained after placebo and after a single dose of 50 mg riluzole using 7-Tesla magnetic resonance spectroscopy (MRS). Within the 22q11.2DS group, the relationship between metabolite concentrations and cognition was examined.

Results: No group differences were found in ACC and striatal metabolite concentrations following placebo. Riluzole numerically decreased ACC ($\eta^2 = 0.094$) but not striatal glutamate concentrations as well as ACC GABA concentrations ($\eta^2 = 0.176$) in all subjects. In both regions, riluzole did not alter glutamine concentration. No interaction effects were found. Although not significant after Bonferroni correction, ACC glutamate concentrations were inversely correlated with cognitive functions in 22q11.2DS patients.

Discussion: We did not demonstrate altered ACC and striatal metabolite concentrations in 22q11.2DS. Nevertheless, these results suggest that glutamate and GABA can be modulated with a single dose of riluzole. Possibly, riluzole may have memory-enhancing effects in 22q11.2DS. Future studies should examine the long-term effects of riluzole on cognition.

Keywords
Glutamate, GABA, 22q11.2DS, riluzole, cognition, 1H-MRS, voltage-gated sodium channel blocker

Introduction
22q11.2 deletion syndrome (22q11.2DS), also referred to as velocardiofacial or DiGeorge syndrome, is a genetic disorder caused by a microdeletion on the long arm of chromosome 22 (Jonas et al., 2014) and is, with a prevalence of 1 in 2000–4000 births, one of the most common recurrent copy number variant disorders (Schneider et al., 2014). Its phenotypic expression is highly heterogeneous and includes medical conditions such as congenital heart disease, palatal anomalies, hypocalcaemia and dysmorphic facial features (Bassett et al., 2011). In addition, 22q11.2DS is associated with a high risk of developing psychiatric disorders, including psychosis spectrum disorders (Schneider et al., 2014) and the majority of 22q11.2DS patients have a below-average IQ and display impairments in cognitive functioning. Cognitive functioning often further declines with age and has been found to be steeper in 22q11.2DS patients developing psychosis (Vorstman et al., 2015).

The typically deleted region is 1.5–3 Mb (megabases) in size, including approximately 90 genes, of which most are expressed

1Department of Psychiatry & Neuropsychology, Maastricht University, Maastricht, the Netherlands
2Department of Radiology & Nuclear Medicine, Amsterdam University Medical Center, Location AMC, Amsterdam, the Netherlands
3Faculty of Psychology and Neuroscience, Maastricht University, Maastricht, the Netherlands
4Department of Psychiatry & UMC Utrecht Brain Center, University Medical Center, Utrecht, the Netherlands
5Department of Radiology, Maastricht University Medical Center, Maastricht University, Maastricht, the Netherlands
6The Sackler Institute for Translational Neurodevelopment, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London, UK

Corresponding author:
Claudia Vingerhoets, Department of Psychiatry & Neuropsychology, Maastricht University, P.O. Box 616 (VUZ-SN2), Maastricht, 6200 MD, the Netherlands.
Email: claudia.vingerhoets@maastrichtuniversity.nl
in the brain (Guna et al., 2015). One of the genes located in the deleted region is the proline dehydrogenase (PRODH) gene, which encodes the enzyme PRODH (also known as proline oxidase), which is important for breaking down proline. Proline is converted to glutamate and acts as a co-agonist at the glutamatergic n-methyl-D-aspartate (NMDA) receptor (Cohen and Nadler, 1997). Observations of increased proline levels in 22q11.2DS have been hypothesized to result from reduced PRODH enzyme activity in 22q11.2DS due to haploinsufficiency of the PRODH gene (Goodman et al., 2000; Vorsman et al., 2009). Decreased PRODH enzyme activity can thus lead to increased proline levels and, subsequently, increased activation of the NMDA receptor and excessive glutamate release (Cohen and Nadler, 1997; Evers et al., 2015; Magnée et al., 2011; Paterlini et al., 2005). Glutamate is the primary excitatory neurotransmitter and is hypothesized to be involved in the pathophysiology of psychosis, with the exception of the rare NMDA-receptor encephalitis disorder and drug states, as well as in cognitive functioning (Lewis and Moghaddam, 2006). Excessive glutamate concentrations are toxic for the brain as this can result in cell death (Lau and Tymianski, 2010). Thus, it could be hypothesized that cognitive decline often observed in 22q11.2DS (Vorstman et al., 2015) is related to prolonged, increased glutamate levels.

Glutamate function is closely correlated with y-aminobutyric acid (GABA): the main inhibitory neurotransmitter in the brain. For example, activity of cortical GABA neurons is partly regulated by glutamatergic inputs (Lewis and Moghaddam, 2006; Marsman et al., 2014). Yet, both systems are often studied in isolation and little is known about GABA in 22q11.2DS. Neuroprotective drugs that modulate glutamatergic neurotransmission and restore the glutamate/GABA balance may effectively enhance cognitive functioning in patients with 22q11.2DS, and possibly reduce disease-associated cognitive decline. One potential candidate drug is riluzole, a Food and Drug Administration-approved glutamate and GABA-modulating compound. Riluzole has neuroprotective properties (Doble, 1996) and is clinically used for the treatment of amyotrophic lateral sclerosis (ALS). Riluzole is a potent antiglutamatergic agent that reduces glutamatergic neurotransmission via several mechanisms of action, including inhibition of presynaptic glutamate release through inactivation of voltage-dependent sodium channels on glutamatergic nerve terminals and calcium currents (Bellingham, 2011; Doble, 1996). Furthermore, riluzole enhances astrocytic glutamate reuptake and reduces the amount of releasable presynaptic glutamate (Lazarevic et al., 2018). In addition, riluzole stimulates GABAergic neurotransmission by stimulating GABAA receptor potentiation and blocking its reuptake (He et al., 2002; Jahn et al., 2008). In other words, riluzole has the potential to restore the glutamate/GABA-balance. Importantly, riluzole has a well-established pharmacokinetic and safety profile, has a low risk of adverse effects, and has been found to be well tolerated in several psychiatric diseases (de Boer et al., 2019; Mathew et al., 2017; Pittenger et al., 2015; Zarate, 2008). Therefore, the aim of the present study was to (a) compare brain concentrations of glutamatergic metabolites (glutamate and glutamine) between patients with 22q11.2DS and controls, (b) to examine the effects of riluzole on these metabolites and (c) within 22q11.2DS to examine the relationship between these metabolites and cognitive functioning. In addition, we explored whether GABA concentrations in the ACC differ between patients and controls, and whether riluzole modulated GABA levels in both groups.

Methods

This study was approved by the Medical Ethical Committee of Maastricht University in the Netherlands (METC142046, NL49834.068.14). All participants gave written informed consent following a full explanation of the study procedure. This study was registered in the Netherlands Trial Register (NTR5095).

Participants

Seventeen 22q11.2DS patients without a history of psychosis, and 20 age and gender matched healthy controls were enrolled in the study. All participants were free of antipsychotic medication at time of scanning. Patients with 22q11.2DS were recruited through the 22q11 outpatient clinic of the academic hospital Maastricht (azM) and through family associations. Healthy participants were recruited via advertisement on the internet. Inclusion criteria were, aged between 18 and 65 years, and for adults with 22q11.2DS, a confirmed diagnosis of 22q11.2DS established by fluorescence in situ hybridization, microarray or multiplex ligation-dependent probe amplification, and the mental capacity to give informed consent. Exclusion criteria for both groups were a history of severe psychiatric or neurological disorders, contraindications for magnetic resonance imaging (MRI) or riluzole and recreational drug use 4 weeks prior to participation. For female participants, pregnancy was an additional exclusion criterion and was verified with a urine screening. All participants were instructed to refrain from alcohol and nicotine 24 h before testing.

Instruments

The full scale intelligence quotient was estimated with a shortend version of the Wechsler Adult Intelligence Scale, version 3 (WAIS-III, (Velthorst et al., 2012)). The Mini International Neuropsychiatric Interview (Sheehan et al., 1997) was used to verify absence of psychiatric disorders. Potential side effects of riluzole were measured with a standardized 31-item self-report inventory using a 4-point Likert scale (0 not affected–3 very affected) (Wezenberg et al., 2005). Cognitive performance was measured with the Cambridge Neuropsychological Test Automated Battery (CANTAB, schizophrenia test battery) (Levaux et al., 2007). This test battery has been well validated and is regarded the ‘gold standard’ of cognitive assessment. CANTAB has been found to be sensitive for pharmacological agents (Barrett et al., 2010) and the sensitivity of the subtests enables detection of subtle effects. We administered the following subtests: Paired Associate Learning, Verbal Recognition Memory, Spatial Working Memory, and Rapid Visual Processing, which cover visual learning and memory, verbal learning and memory, attention and vigilance and working memory, respectively.

1H magnetic resonance spectroscopy

Single-voxel proton magnetic resonance spectroscopy (1H-MRS) measurements were performed on a MAGNETOM 7T MR scanner (Siemens Healthineers, Erlangen, Germany) using a single-channel transmit/32-channel receiving head coil (Nova Medical, Wilmington, MA, USA). Spectra were acquired with a stimulated echo acquisition mode (STEAM) (Frahm et al., 1987) sequence using the following parameters: TE = 6.0 ms, TM=10.0 ms,
TR = 5.0 s, NA = 64, flip angle = 90°, radio frequency (RF) bandwidth = 4.69 kHz, RF centred at 2.4 ppm, receive bandwidth = 4.0 kHz, vector size = 2048, 16-step phase cycling, acquisition time = 5:20 min. Water suppression was achieved by variable power RF pulses with optimized relaxation delays (Tkáč et al., 1999). In addition, a complete phase cycle of measurements was acquired without the water suppression RF pulses, to record a water peak reference for eddy current correction (Klose, 1990) and absolute metabolite concentration calibration (Barker et al., 1993; Soher et al., 1996). Spectroscopic voxels of interest were manually placed by a trained operator at the anterior cingulate cortex (ACC) (voxel size = 25 × 20 × 17 mm³) and the right striatum (voxel size = 20 × 20 × 20 mm³) (Figure 1). Prior to the spectroscopy measurements, a 3D-GRE dual-echo field map (TE1 = 1.00 ms, TE2 = 2.98 ms, TR = 20.0 ms, flip angle = 8°, voxel size = 3 mm isotropic, matrix size = 84 × 84 × 56, bandwidth = 1450 Hz/pixel, acquisition time = 2:24 min) was acquired and used to calculate the shim currents required to homogenise the static magnetic field in the spectroscopic voxels of interest. In addition, an anatomical (T₁-weighted) image was acquired using magnetization-prepared two rapid acquisition gradient-echo (MP2RAGE) (Marques et al., 2010) sequence (TR = 4.5 s, TE = 2.39 ms, T₁ = 0.90 s, T₂ = 2.75 s, flip angle₁ = 5°, flip angle₂ = 3°, voxel size = 0.9 mm isotropic, matrix size = 256 × 256 × 192, phase partial Fourier = 6/8, GRAPPA factor = 3 with 24 reference lines, bandwidth = 250 Hz/pixel, acquisition time = 6:00 min). The spectra were analysed with LCModel version 6.3-1L (Provencher, 2001) using a GAMMA-simulated basis set (Smith et al., 1994). Metabolite concentrations were excluded from statistical analysis when the Cramer–Rao lower bound exceeded 20%. Spectral quality per group (signal to noise ratio and full width at half maximum) is displayed in Supplementary Table 2. Tissue probability maps for grey matter (GM), white matter (WM) and cerebrospinal fluid (CSF) were generated from the T₁-weighted anatomical images using FSL-FAST (Zhang et al., 2015). GM, WM and CSF partial volumes within the spectroscopy voxels were estimated from these tissue probability maps. Metabolite concentrations were corrected for proportion of CSF as described in Quadrelli et al. (2016).

**Procedure**

This study had a randomized double-blind placebo-controlled crossover design. Participants were randomly allocated to either receive placebo or riluzole on the first visit. Ten 22q11.2DS patients and 11 controls received placebo during the first visit. Blinding was done by a research associate who was not involved in any study procedures and both researchers and participants were blind to the order of the intervention. All participants underwent ¹H-MRS measurements twice: once following placebo and once following oral administration of 50 mg riluzole. This dose was chosen as we were interested in the acute effects and to minimize the burden for participants. To assure all participants were free of recreational drugs, a urine drug screen for cannabis,
cocaine, benzodiazepines, opiates, amphetamines and methamphetamines was conducted at the start of each test day. None of the participants tested positive on any of the testing days. Furthermore, no female participants tested positive for pregnancy in a second urine screening. Both testing days started with a brief explanation of the procedure after which the study medication was administered under supervision of the test leader. Scanning commenced 90 min after drug administration given that riluzole reaches $T_{\text{max}}$ approximately 60–90 min after oral administration (Zarate, 2008). To monitor potential adverse effects, a self-report inventory was completed 5 min before scanning. The two scan sessions were separated by at least 1 week to ensure complete drug wash out. The CANTAB and the WAIS-III were always conducted on the first day prior to drug administration, to prevent possible confounding effects of riluzole.

Statistical analyses. All statistical analyses were performed with IBM SPSS Statistics, version 25. First, differences in sample demographics including sex, age, IQ and adverse effects were examined using chi-square or Mann–Whitney U tests respectively. Second, voxel composition was compared between groups using independent sample t-tests (Supplementary Table 1). Group differences in ACC and striatum metabolite concentrations collected during the placebo session were compared (glutamate, glutamine, GABA) using independent sample t-tests. Drug-induced change in metabolite concentrations, as well as group-by-drug interaction, was examined using a repeated measures analyses of variance (rmANOVA). Finally, we examined whether metabolite concentrations were associated with separate cognitive domains (visual memory, verbal memory, working memory and attention) using Spearman’s correlation coefficient as this measure is more robust to the influence of outliers compared to other correlation coefficients (King, 1992; Pillinger et al., 2019). For this purpose, cognitive domain scores were computed for the four cognitive domains (visual memory, verbal memory, working memory, attention). First, the raw scores were converted to standardized Z-scores. The domains for which a lower score represents better performance, were reversed-scored so that a higher score represented better performance for all domains. Bonferroni correction was applied to correct for multiple comparisons ($0.05/3$ (metabolites) $\times 2$ (brain regions) $\times 4$ (cognitive domains)). Consequently, a $p$-value $\leq 0.002$ was considered significant.

Results

Demographics

Sample demographics are displayed in Table 1. No between-group differences were observed for age ($t(1,36) = -1.05, p = 0.304$) and sex ($\chi^2(1) = 0.09, p = 0.769$). Patients with 22q11.2DS had a significantly lower IQ compared with healthy controls ($t(1,36) = 8.99, p < 0.001$). Riluzole and placebo session side effect scores did not differ across the entire sample ($U = 113.0, p = 0.186$).

1H-MRS metabolite concentrations

We did not find differences in metabolite concentrations after placebo between groups (Table 2). However, glutamate concentrations were numerically higher in 22q11.2DS patients with an effect size in the medium range ($d = 0.528$). We observed a trend in decreased ACC glutamate concentrations after riluzole administration in the total sample (Figure 2a), although this effect did not reach significance despite a medium–high effect size ($F(1,35) = 3.61, p = 0.066, \eta^2 = 0.094$). No group-by-drug interaction effect was observed ($F(1,35) = 0.11, p = 0.738, \eta^2 = 0.003$). No evidence for a main effect of riluzole on striatal glutamate concentrations was observed ($F(1,34) = 0.19, p = 0.669, \eta^2 = 0.005$), nor was a group-by-drug interaction ($F(1,34) = 0.02, p = 0.904, \eta^2 = 0.000$). No main or group-by-drug interaction effect of riluzole was observed for either ACC or striatal glutamine.

Table 1. Sample demographics.

|                      | HC Mean (SD) | 22q11.2DS Mean (SD) | Statistic | p-value |
|----------------------|--------------|---------------------|-----------|---------|
| Sex (m/f)            | 8/12         | 6/11                | 0.09      | 0.769   |
| Age                  | 30.7 (8.20)  | 34.17 (11.41)       | -1.05     | 0.304   |
| FSIQ                 | 120.2 (16.23)| 76.65 (12.32)       | 8.99      | <0.001  |
| Side effects         |              |                     |           |         |
| Placebo              | 3.42 (4.7)   | 3.50 (3.1)          | 128.5     | 0.428   |
| Riluzole             | 2.42 (4.1)   | 4.25 (4.3)          | 113.0     | 0.186   |
| SSRI use (no/yes)    | 19/1         | 15/2                | 0.56      | 0.452   |

Note: FSIQ: full scale intelligence quotient; SSRI: selective serotonin reuptake inhibitor; HC: healthy controls. Significant results are bold.

Table 2. Baseline metabolite concentrations, CSF corrected.

|                      | HC Mean (SD)      | 22q11.2DS Mean (SD) | CRLB in % | 95% CI lower–upper | p   | d     |
|----------------------|-------------------|---------------------|-----------|-------------------|-----|-------|
| ACC                  |                    |                     |           |                   |     |       |
| Glutamate            | 20 6.659 (0.66)    | 17 7.061 (0.85)     | 2.3 (0.45)| -0.90 to 0.10     | 0.115| 0.528 |
| GABA                 | 15 0.930 (0.18)    | 14 0.890 (0.28)     | 11.7 (3.42)| -0.14 to 0.22     | 0.651| 0.084 |
| Glutamine            | 12 0.816 (0.20)    | 14 0.801 (0.23)     | 9.1 (2.69)| -0.13 to 0.16     | 0.834| 0.070 |
| Striatum             |                    |                     |           |                   |     |       |
| Glutamate            | 20 4.419 (0.63)    | 16 4.628 (0.80)     | 4.2 (1.62)| -0.68 to 0.27     | 0.380| 0.290 |
| Glutamine            | 13 1.181 (0.32)    | 12 1.132 (0.42)     | 11.1 (2.92)| -0.23 to 0.32     | 0.717| 0.131 |

Note: ACC: anterior cingulate cortex; CSF: cerebral spinal fluid; CI: confidence interval for difference; CRLB: Cramer–Rao lower bound.
concentrations (Table 3). Finally, GABA concentrations in the ACC decreased in both groups after riluzole administration ($F(1,24) = 5.14, p = 0.033, \eta^2 = 0.176$). Whiskers in (a) and (b) indicate minimum and maximum values.

### Table 3. Effects of riluzole on brain metabolites.

|                | Healthy controls | 22q11.2DS | ACC Glutamate | ACC Glutamine | ACC GABA | Striatum Glutamate | Striatum Glutamine |
|----------------|------------------|-----------|---------------|---------------|---------|-------------------|-------------------|
|                | Placebo          | Riluzole  | Placebo       | Riluzole      | 95% CI  | Placebo           | Riluzole          |
| N              | Mean (SD)        | Mean (SD) | Mean (SD)     | Mean (SD)     | Lower–upper | Mean (SD)        | Mean (SD)        |
| ACC Glutamate  | 20               | 6.659 (0.66) | 6.477 (0.64) | 17            | 7.061 (0.85) | 6.800 (0.63)     | $-0.015$ to $0.458$ | $0.066$ | $0.094$ | $0.738$ | $0.003$ |
| ACC Glutamine  | 19               | 0.816 (0.20) | 0.832 (0.23) | 16            | 0.785 (0.22) | 0.794 (0.25)    | $-0.085$ to $0.059$ | $0.712$ | $0.004$ | $0.928$ | $0.000$ |
| ACC GABA       | 12               | 0.938 (0.25) | 0.775 (0.16) | 14            | 0.975 (0.34) | 0.874 (0.19)    | $-0.023$ to $0.195$ | $\textbf{0.033}$ | $0.176$ | $0.603$ | $0.011$ |
| Striatum Glutamate | 20           | 4.419 (0.63) | 4.389 (0.70) | 16            | 4.674 (0.80) | 4.620 (0.76)    | $-0.691$ to $0.205$ | $0.669$ | $0.005$ | $0.904$ | $0.000$ |
| Striatum Glutamine | 13          | 1.151 (0.32) | 1.137 (0.36) | 12            | 1.025 (0.23) | 0.950 (0.30)    | $-0.024$ to $0.113$ | $0.196$ | $0.072$ | $0.370$ | $0.035$ |

Note: ACC: anterior cingulate cortex; CI: confidence interval for difference. Significant effects are bold.

### Discussion

Here, we examined whether ACC and striatal glutamatergic metabolite concentrations are altered in adults with 22q11.2DS and if a single dose of riluzole modulates these metabolites. Despite a medium effect size, we found no group differences in ACC and striatal metabolite concentrations following placebo administration. This is in line with studies by Rogdaki et al. (2018) and da Silva Alves et al. (2011), neither of whom found differences in frontal levels of the glutamate + glutamine complex (Glx) between patients with 22q11.2DS and healthy controls. Yet, da Silva Alves et al. (2011) did report higher hippocampal Glx concentrations in 22q11.2DS patients with a psychotic disorder compared with 22q11.2DS patients without psychosis and healthy controls, consistent with findings of higher frontal Glx levels in patients with psychosis without 22q11.2DS (Merritt et al., 2016). This may indicate that glutamatergic alterations may be a ‘state’ rather than a ‘trait’ characteristic of psychosis (Rogdaki et al., 2018) and/or may be region specific. However, both Rogdaki et al. (2018) and da Silva Alves et al. (2011) used 3-Tesla MRI and therefore were not able to differentiate between glutamate and glutamine. Using 7-Tesla we were able to measure both glutamate and glutamine separately due to increased spatial and spectral resolution at 7-Tesla (Mekle et al., 2009). Given that
our sample was small, and the p-value relatively low with a corresponding medium effect size, we cannot exclude the possibility that glutamate levels (rather than glutamine) may be marginally heightened in 22q11.2DS without psychosis.

Interestingly, we observed a trend in decreased glutamate levels after riluzole in the ACC, but not striatal, glutamate concentrations, whereas no effect of riluzole on glutamine was found in either brain regions. Although not reaching significance in this small sample, the medium to large effect size implies that riluzole is able to modulate glutamate neurotransmission, even after a single administration. Moreover, our results suggest that it primarily targets glutamate rather than other glutamatergic metabolites. Furthermore, we found that higher ACC glutamate concentrations in the placebo condition were associated with poorer visual and verbal memory performance in 22q11.2DS (although not significant after Bonferroni correction), implicating that glutamatergic neurotransmission may be involved in some of the cognitive deficits observed in 22q11.2DS. Although not significant after Bonferroni correction, GABA levels were also inversely associated with memory and attention. In line with findings in other neurological/psychiatric disorders including psychosis (Lewis and Moghadam, 2006; Merritt et al., 2013; Taylor and Tso, 2015; Vingerhoets et al., 2013), this confirms a role of glutamate and GABA in cognitive impairments in 22q11.2DS. Modulation of glutamate/GABA neurotransmission may therefore be a target for pharmacological treatment of cognitive symptoms in patients with 22q11.2DS. Since our results suggest that riluzole modulates both glutamate and GABA in 22q11.2DS, this compound may be an effective treatment for cognitive impairment in 22q11.2DS. Indeed, improvement in memory and attention was found in a female patient with 22q11.2DS after 18 months of treatment with riluzole (Vingerhoets et al., 2019). Unfortunately, in this study we only used a single dose of riluzole and we only conducted cognitive tests at baseline in order to minimize the burden for participants. Hence, future studies examining cognition-enhancing effects of long-term riluzole treatment are warranted.

A study by Pillinger et al. (2019) reported decreased ACC Glx concentrations in treatment-resistant schizophrenia patients following a 2-day challenge with 50 mg riluzole twice daily using 3T MRS, whereas we found a trend for reduced glutamate but not glutamine concentrations following a single dose of riluzole. In addition, Brennan et al. (2010) reported an increased glutamate/glutamate ratio in bipolar depression after a similar 2-day riluzole challenge using 3T MRS. However, both these studies used a repeated administration design whereas we only administered a single (low) dose of riluzole. A possible explanation for the divergent results is that changes in glutamate and/or glutamine only occur after multiple and/or higher riluzole doses. Another possibility is that riluzole has different effects in pathological and non-pathological conditions, as both Pillinger et al. (2019) and Brennan et al. (2010) included individuals with a psychiatric disorder, whereas our 22q11.2DS sample had no history of psychiatric disorders. Moreover, in contrast to our sample, patients in both studies were using antipsychotic or antidepressant medication, which could have interacted with riluzole’s mechanisms of action. It is worth mentioning that both previous studies were conducted at lower MR field strength and consequently were not able to reliably distinguish glutamate and glutamine. Previous results obtained at 3T may therefore reflect changes in glutamate rather than glutamine. Indeed, when looking at the effect sizes, we observed a medium to large effect of riluzole on ACC glutamate concentrations, whereas its effect on glutamine in this region appears to be small. Contrarily, we found a medium effect size of riluzole on striatal glutamine whereas the effect on striatal glutamate was small. This could indicate that riluzole’s mechanism of action differs between cortical and subcortical regions. This would seem consistent with the observation that, in rodents, a decrease in striatal glutamate was only observed at high riluzole doses, whereas a decrease in prefrontal cortex glutamate concentrations was already visible after a low dose of riluzole (Waschkies et al., 2014). In line with our results, no changes were observed in glutamine concentrations in either region at low, medium or high dosages (Waschkies et al., 2014).

Finally, exploratory analyses showed a decrease (main effect of drug) in ACC GABA concentrations after riluzole administration. The mechanism of action of riluzole is complex and currently, not completely understood. Nonetheless, although riluzole preferentially inhibits glutamate release, it has also been reported to influence GABAergic transmission (Jahn et al., 2008; Jehle et al., 2000). While both pre- and postsynaptic effects of riluzole on GABAergic transmission have been established, postsynaptic potentiating effects of riluzole on GABA_A receptors have only been reported at higher dosages (He et al., 2002). This could be a possible explanation for the decrease in ACC GABA concentrations given that the dosage used in this study was relatively low. Indeed Ajram et al. (2017) reported decreased prefrontal GABA concentrations in healthy controls following the same dose of riluzole, and an increase in patients with autism spectrum disorders. Unfortunately, to the best of our knowledge, no other in vivo studies examining effects of a higher dosage of riluzole on GABA concentrations in humans have been conducted.

**Strengths and limitations**

A major strength of this study is the use of 7T MRI. At 3T, glutamate and glutamine cannot be reliably distinguished and are therefore typically measured as the Glx. Due to increased spectral resolution at 7T we were able to reliably obtain separate measures of glutamate and glutamine. Moreover, 7T allows for quantification of GABA resulting in relatively higher variance of GABA concentrations (Table 2). Therefore, results regarding GABA should be considered exploratory and interpreted with care. Future studies could use a separate sequence optimized for GABA measurement to further reduce variance.

Furthermore, subjects had no diagnosis of a psychotic disorder and were antipsychotic naïve at time of inclusion. Since psychotic disorders are also associated with glutamatergic alterations, our results reflect glutamatergic alterations related to the 22q11.2 deletion. Another potential drawback may be that inclusion criteria for 7T MRI are stringent and no implants are allowed. Many patients with 22q11.2DS carry metal implants due to congenital heart problems or scoliosis. This may have caused a selection bias of relatively healthy patients. Furthermore, the sample size of our study was relatively small, resulting in limited power to detect group differences and may explain the lack of statistically significant group differences. However, the medium to large effect sizes suggest that results may have reached significance in a bigger sample. Another limitation is that we used a single,
relatively low dose of riluzole, which could explain the lack of a significant effect of riluzole on glutamate. The recommended daily dosage in ALS is 100 mg (50 mg twice daily) (Bruno et al., 1997). We chose this dose as we were interested in acute effects and wanted to minimize the burden for the participants. However, other studies in treatment-resistant schizophrenia (Pillinger et al., 2019) and depression (Brennan et al., 2010) showed a decrease in glutamate concentrations after a 2-day challenge with 100 mg riluzole. Future studies should examine the effects of long-term riluzole treatment in a larger sample of 22q11.2DS patients. With regard to 1H-MRS, an important limitation of this method is that it does not enable precise localization of glutamatergic metabolites (e.g. intracellular vs. extracellular and pre- vs. postsynaptic).

In conclusion, we demonstrated that a single dose of riluzole decreases ACC glutamate concentrations at trend level in 22q11.2DS. Given the inverse correlation between glutamate and memory in 22q11.2DS, modulation of the glutamate/GABA system using riluzole may have cognitive-enhancing effects in 22q11.2DS. Given glutamate’s role in psychotic disorders and findings of increased Glx levels in psychosis, future studies should examine whether riluzole treatment could also enhance cognition in a bigger sample of 22q11.2DS patients. However, more studies are required to replicate these findings and to examine the effects of long-term treatment with riluzole.

Authors’ note
University Fund Limburg had no role in the study design, collection, analysis and interpretation of the data, in the writing of the report or in the decision to submit the paper for publication.

Acknowledgements
We would like to thank all subjects for participating in this study. We would also like to thank Esther Steijvers for her help scanning the participants, Debora op ’t Eijnde and Nele Volbragt for study coordination and Nele Soons for helping with recruitment.

Author contribution
TvA designed the study and TvA and CV wrote the protocol. CV managed the literature searches and analyses. Imaging analyses were performed by CV and DHYT. Statistical analyses were conducted by CV. MvO and EvD assisted with testing of the participants. DH, JZ, JGR, JFAJ and GM advised on the study set-up and data analyses. CV wrote the first draft of the manuscript. All authors contributed to and approved the final manuscript.

Declaration of conflicting interests
The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding
The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was funded by University Fund Limburg (grant no. S.2014.11).

ORCID iD
Claudia Vingerhoets https://orcid.org/0000-0001-7790-5041

Supplemental material
Supplemental material for this article is available online.

References
Ajam LA, Horder J, Mendez MA, et al. (2017) Shifting brain inhibitory balance and connectivity of the prefrontal cortex of adults with autism spectrum disorder. *Transl Psychiatry* 7: e1337.
Barker PB, Soher BJ, Blackband SJ, et al. (1993) Quantitation of proton NMR spectra of the human brain using tissue water as an internal concentration reference. *NMR Biomed* 6: 89–94.
Barnett JH, Robbins TW, Leeson VC, et al. (2010) Assessing cognitive functioning in clinical trials of schizophrenia. *Neurosci Biobehav Rev* 34: 1161–1177.
Bassett AS, McDonald-McGinn DM, Devriendt K, et al. (2011) Practical guidelines for managing patients with 22q11.2 deletion syndrome. *J Pediatr* 159:332–339.e1.
Bellingham MC (2011) A review of the neural mechanisms of action and clinical efficiency of riluzole in treating amyotrophic lateral sclerosis: What have we learned in the last decade? *CNS Neurosci Ther* 17: 4–31.
Brennan BP, Hudson JI, Jensen JE, et al. (2010) Rapid enhancement of glutamatergic neurotransmission in bipolar depression following treatment with riluzole. *Neuropsychopharmacology* 35: 834–846.
Bruno R, Vivier N, Montay G, et al. (1997) Population pharmacokinetics of riluzole in patients with amyotrophic lateral sclerosis. *Clin Pharmacol Ther* 62: 518–526.
Cohen SM and Nadler JV (1997) Proline-induced potentiation of glutamate transmission. *Brain Res* 761: 271–282.
da Silva Alves F, Boot E, Schmitz N, et al. (2011) Proton magnetic resonance spectroscopy in 22q11 deletion syndrome. *PLoS One* 6: e21685.
de Boer JN, Vingerhoets C, Hirdes M, et al. (2019) Efficacy and tolerability of riluzole in psychiatric disorders: A systematic review and preliminary meta-analysis. *Psychiatry Res* 278: 294–302.
Doble A (1996) The pharmacology and mechanism of action of riluzole. *Neurology* 47(6 Suppl. 4): S233–S241.
Evers LJM, van Amelsvoort TAMJ, Bakker JA, et al. (2015) Glutamatergic markers, age, intellectual functioning and psychosis in 22q11 deletion syndrome. *Psychopharmacology* 232: 3319–3325.
Frahm J, Merboldt KD and Hänicke W (1987) Localized proton spectroscopy using stimulated echoes. *J Magn Reson* 72: 502–508.
Goodman BK, Rutherg J, Lin WW, et al. (2000) Hyperprolinaemia in patients with deletion (22)(q11.2) syndrome. *J Inherit Metab Dis* 23: 847–848.
Guna A, Butcher NJ and Bassett AS (2015) Comparative mapping of the 22q11.2 deletion region and the potential of simple model organisms. *J Neurodev Disord* 7: 18.
He Y, Benz A, Fu T, et al. (2002) Neuroprotective agent riluzole potentiates postsynaptic GABA(A) receptor function. *Neuropharmacology* 42: 199–209.
Jahn K, Schlesinger F, Jin LJ, et al. (2008) Molecular mechanisms of interaction between the neuroprotective substance riluzole and GABA(A)-receptors. *Naunyn Schmiedebergs Arch Pharmacol* 378: 53–63.
Jehle T, Bauer J, Blauth E, et al. (2000) Effects of riluzole on electrically evoked neurotransmitter release. *Br J Pharmacol* 130: 1227–1234.
Jonas RK, Montojo CA and Bearden CE (2014) The 22q11.2 deletion syndrome as a window into complex neuropsychiatric disorders over the lifespan. *Biol Psychiatry* 75: 351–360.
King M (1992) Practical statistics for medical research. *J Psychosom Res* 36: 603–603.
Klose U (1990) In vivo proton spectroscopy in presence of eddy currents. *Magn Reson Med* 14: 26–30.
Lau A and Tymianski M (2010) Glutamate receptors, neurotoxicity and neurodegeneration. *Pflugers Arch* 460: 525–542.
Lazarevic V, Yang Y, Ivanova D, et al. (2018) Riluzole attenuates the efficacy of glutamatergic transmission by interfering with the size of the readily releasable neurotransmitter pool. *Neuropharmacology* 143: 38–48.
Levaux M-N, Potvin S, Sepehry AA, et al. (2007) Computerized assessment of cognition in schizophrenia: Promises and pitfalls of CANTAB. *Eur Psychiatry* 22: 104–115.

Lewis DA and Moghaddam B (2006) Cognitive dysfunction in schizophrenia: Convergence of gamma-aminobutyric acid and glutamate alterations. *Arch Neurol* 63: 1372–1376.

Magnee MCM, Lamme VAF, de Sain-van der Velden MGM, et al. (2011) Proline and COMT status affect visual connectivity in children with 22q11.2 deletion syndrome. *PLoS One* 6: e25882.

Marques JP, Kober T, Krueger G, et al. (2010) MP2RAGE, a self bias-field corrected sequence for improved segmentation and T1-mapping at high field. *Neuroimage* 49: 1271–1281.

Marsman A, Mandl RCW, Klomp DWJ, et al. (2014) GABA and glutamate in schizophrenia: A 7 T 1H-MRS study. *Neuroimage Clin* 6: 398–407.

Mathew SJ, Gueorguieva R, Brandt C, et al. (2017) A randomized, double-blind, placebo-controlled, sequential parallel comparison design trial of adjunctive riluzole for treatment-resistant major depressive disorder. *Neuropsychopharmacology* 42: 2567–2574.

Mekle R, Mlynárik V, Gambarota G, et al. (2009) MR spectroscopy of the human brain with enhanced signal intensity at ultrashort echo times on a clinical platform at 3T and 7T. *Magn Reson Med* 61: 1279–1285.

Merritt K, Egerton A, Kempton MJ, et al. (2016) Nature of glutamate alterations in schizophrenia: A meta-analysis of proton magnetic resonance spectroscopy studies. *JAMA Psychiatry* 73: 665–674.

Merritt K, McGuire P and Egerton A (2013) Relationship between glutamate dysfunction and symptoms and cognitive function in psychosis. *Front Psychiatry* 4: 151.

Paterlini M, Zakharenko SS, Lai W-S, et al. (2005) Transcriptional and behavioral interaction between 22q11.2 orthologs modulates schizophrenia-related phenotypes in mice. *Nat Neurosci* 8(11): 1586–1594.

Pillinger T, Rogdaki M, Mccutcheon RA, et al. (2019) Altered glutamatergic response and functional connectivity in treatment resistant schizophrenia: The effect of riluzole and therapeutic implications. *Psychopharmacology (Berl)* 236: 1985–1997.

Pittenger C, Bloch MH, Wasylink S, et al. (2015) Riluzole augmentation in treatment-refractory obsessive-compulsive disorder. *J Clin Psychiatry* 76: 1075–1084.

Provencher SW (2001) Automatic quantitation of localized in vivo 1H spectra with LCModel. *NMR Biomed* 14: 260–264.

Quadrelli S, Mountford C and Ramadan S (2016) Hitchhiker’s guide to voxel segmentation for partial volume correction of in vivo magnetic resonance spectroscopy. *Magn Reson Insight* 9: 1–8.

Rogdaki M, Veronese M, Hathway P, et al. (2018) The state or trait component of dopamine and glutamate dysfunction in the risk for psychosis: An in-vivo multimodal imaging study of individuals with 22q11.2 deletion. *Schizophr Bull* 44(Suppl. 1): S395.

Schneider M, Debbane M, Bassett AS, et al. (2014) Psychiatric disorders from childhood to adulthood in 22q11.2 deletion syndrome: Results from the international consortium on brain and behavior in 22q11.2 deletion syndrome. *Am J Psychiatry* 171: 627–639.

Sheehan D, Lecrubier Y, Harnett Sheehan K, et al. (1997) The validity of the Mini International Neuropsychiatric Interview (MINI) according to the SCID-P and its reliability. *Eur Psychiat* 12: 232–241.

Smith SA, Levante TO, Meier BH, et al. (1994) Computer simulations in magnetic resonance. An object-oriented programming approach. *J Magn Reson A* 106: 75–105.

Soher BJ, Hurd RE, Sailsauna N, et al. (1996) Quantitation of automated single-voxel proton MRS using cerebral water as an internal reference. *Magn Reson Med* 36: 335–339.

Taylor SF and Tso IF (2015) GABA abnormalities in schizophrenia: A methodological review of in vivo studies. *Schizophrenia Res* 167: 84–90.

Tkáč I, Stačík Z, Choi JY, et al. (1999) In vivo 1H NMR spectroscopy of rat brain at 1 ms echo time. *Magn Reson Med* 41: 649–656.

Velthorst E, Levine SZ, Henquet C, et al. (2012) To cut a short test even shorter: Reliability and validity of a brief assessment of intellectual ability in Schizophrenia-a control-case family study. *Cogn Neuropsychiatry* 18: 37–41.

Vingerhoets C, Tse DHY and van Amelsvoort T (2019) Riluzole effectively treats psychotic symptoms and improves cognition in 22q11.2 deletion syndrome: A clinical case. *Eur J Med Genet* 62: 103705.

Vingerhoets WAM, Bloemen OJN, Bakker G, et al. (2013) Pharmacological interventions for the MATRICS cognitive domains in schizophrenia: What’s the evidence? *Front Psychiatry* 4: 157.

Vorstman JAS, Breetvelt EJ, Duifff SN, et al. (2015) Cognitive decline preceding the onset of psychosis in patients with 22q11.2 deletion syndrome. *JAMA Psychiatry* 72: 377–385.

Vorstman JAS, Turetsky BI, Sijmens-Morcu MEJ, et al. (2009) Proline affects brain function in 22q11DS children with the low activity COMT 158 allele. *Neuropsychopharmacology* 34: 739–746.

Waschkies CF, Bruns A, Müller S, et al. (2014) Neupropharmacological and neurobiological relevance of in vivo 1H-MRS of GABA and glutamate for preclinical drug discovery in mental disorders. *Neuropsychopharmacology* 39: 2331–2339.

Wezenberg E, Verkes RJ, Sabbe BGC, et al. (2005) Modulation of memory and visuospatial processes by biperiden and rivastigmine in Alzheimer’s disease. *Neuroimage* 23: 120–127.

Wezenberg E, Verkes RJ, Sabbe BGC, et al. (2005) Computerized assessment of cognition in schizophrenia: Promises and pitfalls of CANTAB. *Eur Psychiatry* 22: 104–115.

Wijtenburg SA, Rowland LM, Edden RAE, et al. (2013) Reproducibility and neurobiological relevance of in vivo 1 H-MRS of GABA and glutamate for preclinical drug discovery in mental disorders. *Neuropsychopharmacology* 39: 2331–2339.

Zhang Y, Brady M and Smith S (2015) Segmentation of brain MR images with an adaptive level set and multiresolution SNRF. *Magn Reson Imaging* 33: 1–12.

Zhang Y, Brady M and Smith S (2015) Segmentation of brain MR images with an adaptive level set and multiresolution SNRF. *Magn Reson Imaging* 33: 1–12.